{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:54:31Z","timestamp":1789512871178,"version":"build-2803163510"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T00:00:00Z","timestamp":1353283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"DOI":"10.1002\/jbmr.1800","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T13:43:13Z","timestamp":1353332593000},"page":"2419-2428","source":"Crossref","is-referenced-by-count":124,"title":["Safety of osteoanabolic therapy: A decade of experience"],"prefix":"10.1093","volume":"27","author":[{"given":"Cristiana","family":"Capriani","sequence":"first","affiliation":[{"name":"Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinaz","family":"Irani","sequence":"additional","affiliation":[{"name":"Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,11,19]]},"reference":[{"key":"2024020318322710000_bib1","year":"2010"},{"key":"2024020318322710000_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol."},{"issue":"7","key":"2024020318322710000_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1\u201384. in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol Pathol."},{"issue":"3","key":"2024020318322710000_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cmet.2009.07.010","article-title":"T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling","volume":"10","author":"Terauchi","year":"2009","journal-title":"Cell Metab."},{"issue":"11","key":"2024020318322710000_bib5","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology."},{"issue":"1","key":"2024020318322710000_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1615\/CritRevEukaryotGeneExpr.v13.i1.30","article-title":"The cellular and clinical parameters of anabolic therapy for osteoporosis","volume":"13","author":"Rosen","year":"2003","journal-title":"Crit Rev Eukaryot Gen Expr."},{"issue":"6","key":"2024020318322710000_bib7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1084\/jem.20050354","article-title":"Identifying genes that regulate bone remodeling as potential therapeutic targets","volume":"201","author":"Krane","year":"2005","journal-title":"J Exp Med."},{"issue":"7","key":"2024020318322710000_bib8","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/jc.2003-032066","article-title":"Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone. (1\u201334)","volume":"89","author":"Buxton","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2024020318322710000_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11914-008-0005-9","article-title":"Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window","volume":"6","author":"Bilezikian","year":"2008","journal-title":"Curr Osteoporos Rep."},{"key":"2024020318322710000_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.1992.tb02323.x","article-title":"Treatment of osteoporosis with parathyroid peptide (hPTH 1\u201334) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone","volume":"37","author":"Bradbeer","year":"1992","journal-title":"Clin Endocrinol."},{"issue":"2","key":"2024020318322710000_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","article-title":"Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1\u201334) therapy in women with severe osteoporosis","volume":"27","author":"Hodsman","year":"2000","journal-title":"Bone."},{"key":"2024020318322710000_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bone.2008.09.019","article-title":"Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone. 1\u201384","volume":"44","author":"Recker","year":"2009","journal-title":"Bone."},{"key":"2024020318322710000_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0169-6009(91)90103-7","article-title":"Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1\u201338) and salmon calcitonin in osteoporotic patients","volume":"14","author":"Hodsman","year":"1991","journal-title":"Bone Miner."},{"key":"2024020318322710000_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01625448","article-title":"hPTH 1\u201334 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses","volume":"1","author":"Reeve","year":"1991","journal-title":"Osteoporos Int."},{"key":"2024020318322710000_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jbmr.5650010411","article-title":"Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1\u201334) and 1,25-dihydroxyvitamin D","volume":"1","author":"Slovik","year":"1986","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib17","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) (teriparatide) improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib18","first-page":"S97","article-title":"Assessment of effects of ly333334 [recombinant human parathyroid hormone (1\u201334)] on cortical bone using digital x-ray radiogrammetry","volume":"28","author":"Hyldstrup","year":"2002","journal-title":"Bone."},{"key":"2024020318322710000_bib19","first-page":"S208","article-title":"Teriparatide [rhPTH(1\u201334)] improves the structural geometry of the hip","volume":"17","author":"Uusi-Rasi","year":"2002","journal-title":"J Bone Miner Res."},{"issue":"19","key":"2024020318322710000_bib20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"issue":"2","key":"2024020318322710000_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han","year":"2012","journal-title":"Int J Clin Pract."},{"issue":"6","key":"2024020318322710000_bib22","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318322710000_bib23","author":"Crandall"},{"issue":"9156","key":"2024020318322710000_bib24","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet."},{"issue":"9","key":"2024020318322710000_bib25","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endrocrinol Metab."},{"issue":"1","key":"2024020318322710000_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide (human parathyroid hormone (1\u201334)) therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020318322710000_bib27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporosis Int."},{"issue":"20","key":"2024020318322710000_bib28","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med."},{"issue":"11","key":"2024020318322710000_bib29","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"11","key":"2024020318322710000_bib30","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone (1\u201384) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318322710000_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med."},{"issue":"11","key":"2024020318322710000_bib32","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1185\/03007995.2010.524121","article-title":"Treatment of postmenopausal women with osteoporosis with PTH (1\u201384) for 36 months: treatment extension study","volume":"26","author":"Zanchetta","year":"2010","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"2024020318322710000_bib33","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1210\/jc.2004-0826","article-title":"Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures","volume":"90","author":"Gallagher","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"15","key":"2024020318322710000_bib34","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med."},{"issue":"11","key":"2024020318322710000_bib35","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.060802","article-title":"Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis","volume":"21","author":"Chen","year":"2006","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","article-title":"New understanding and treatments for osteoporosis","volume":"41","author":"Mazziotti","year":"2012","journal-title":"Endocrine."},{"key":"2024020318322710000_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1\u201334. vs calcitriol,calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA."},{"key":"2024020318322710000_bib38","first-page":"3480","article-title":"Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone. 1\u201334 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318322710000_bib39","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone (1\u201334) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024020318322710000_bib40","first-page":"391","article-title":"Synthetic human parathyroid hormone. 1\u201334. replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318322710000_bib41","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"and the hypoparathyroid study group. The effect of adding PTH (1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib42","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024020318322710000_bib43","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1\u201384) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib44","author":"Bilezikian","year":"2012","journal-title":"Efficacy of recombinant human parathyroid hormone (rhPTH[1\u201384]) for the treatment of adults with hypoparathyroidism: a randomized, double-blind, placebo-controlled study. Presented at The 94th Annual Meeting of The Endocrine Society;."},{"key":"2024020318322710000_bib45","article-title":"Effect of recombinant human parathyroid hormone (rhPTH[1\u201384]) on skeletal dynamics and BMD in hypoparathyroidism: the REPLACE study","author":"Bilezikian","year":"2012","journal-title":"Presented at the ASBMR Annual Meeting;."},{"key":"2024020318322710000_bib46","article-title":"Treatment of hypoparathyroidism with PTH (1\u201384) is safe and effective for up to 4 years","author":"Cusano","year":"2011","journal-title":"Presented at the ASBMR Annual Meeting;."},{"key":"2024020318322710000_bib47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12020-012-9618-y","article-title":"Mini-review: new therapeutic options in hypoparathyroidism","volume":"41","author":"Cusano","year":"2012","journal-title":"Endocrine."},{"issue":"1","key":"2024020318322710000_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-010-9360-5","volume":"87","author":"Ellegaard","year":"2010","journal-title":"Parathyroid hormone and bone healing Calcif Tissue Int."},{"issue":"2","key":"2024020318322710000_bib49","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1359\/jbmr.090731","article-title":"Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures","volume":"25","author":"Aspenberg","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"17","key":"2024020318322710000_bib50","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2106\/JBJS.J.01379","article-title":"Parathyroid hormone. 1\u201384. accelerates fracture-healing in pubic bones of elderly osteoporotic women","volume":"93","author":"Peichl","year":"2011","journal-title":"J Bone Joint Surg Am."},{"key":"2024020318322710000_bib51"},{"issue":"9","key":"2024020318322710000_bib52","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1210\/jc.2011-0593","article-title":"Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide","volume":"96","author":"Carvalho","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2024020318322710000_bib53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","article-title":"Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1\u201334)]","volume":"65","author":"Harper","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"issue":"8","key":"2024020318322710000_bib54","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.081176","article-title":"Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1\u201334)] therapy","volume":"36","author":"Lau","year":"2009","journal-title":"J Rheumatol."},{"issue":"4","key":"2024020318322710000_bib55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol."},{"issue":"6","key":"2024020318322710000_bib56","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1359\/jbmr.080208","article-title":"Perspective on the interpretation of rat carcinogenicity studies for human PTH(1\u201334) and human PT. H(1\u201384)","volume":"23","author":"Tashjian","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024020318322710000_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ijc.24320","article-title":"International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons","volume":"125","author":"Mirabello","year":"2009","journal-title":"Int J Cancer."},{"key":"2024020318322710000_bib58","doi-asserted-by":"crossref","first-page":"548151","DOI":"10.1155\/2011\/548151","article-title":"Using epidemiology and genomics to understand osteosarcoma etiology","volume":"2011","author":"Savage","year":"2011","journal-title":"Sarcoma."},{"issue":"7","key":"2024020318322710000_bib59","first-page":"1531","article-title":"Osteosarcoma incidence and survival rates from. 1973 to 2004: data from the Surveillance","volume":"115","author":"Mirabello","year":"2009","journal-title":"Epidemiology, and End Results Program. Cancer."},{"key":"2024020318322710000_bib60","author":"U.S. Department of Health and Human Services"},{"issue":"3","key":"2024020318322710000_bib61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2131\/jts.37.617","article-title":"Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1\u201334))","volume":"37","author":"Watanabe","year":"2012","journal-title":"J Toxicol Sci."},{"issue":"2","key":"2024020318322710000_bib62","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(00)00430-0","article-title":"Treatment with human parathyroid hormone (1\u201334) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)","volume":"28","author":"Jerome","year":"2001","journal-title":"Bone."},{"issue":"3","key":"2024020318322710000_bib63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(99)00166-0","article-title":"Effect of treatment for 6 months with human parathyroid hormone (1\u201334) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis)","volume":"25","author":"Jerome","year":"1999","journal-title":"Bone."},{"issue":"12","key":"2024020318322710000_bib64","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1359\/jbmr.080807","article-title":"Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1\u201334)]","volume":"23","author":"Vahle","year":"2008","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4615-0651-5_17","volume-title":"Non-invasive assessment of trabecular bone architecture and the competence of bone","author":"Turner","year":"2001"},{"issue":"2","key":"2024020318322710000_bib66","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1359\/jbmr.061101","article-title":"Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1\u201384) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine","volume":"22","author":"Fox","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.1768","article-title":"The US Postmarketing Surveillance Study of Adult Osteosarcoma Teriparatide study design findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"JBMR."},{"issue":"2","key":"2024020318322710000_bib68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide?","volume":"22","author":"Harper","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2024020318322710000_bib69","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","article-title":"Of mice and men: divergent risks of teriparatide-induced osteosarcoma","volume":"21","author":"Subbiah","year":"2010","journal-title":"Osteoporos Int."},{"issue":"(Suppl 1","key":"2024020318322710000_bib70","first-page":"SU0354","article-title":"Case report: osteosarcoma and teriparatide (abstract). Poster presented at the ASBMR 31st Annual Meeting","author":"Lubitz","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/IJWH.S4920","article-title":"Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH(1\u201384) in the treatment of postmenopausal osteoporosis","volume":"1","author":"Pietrogrande","year":"2009","journal-title":"Int J Womens Health."},{"issue":"7","key":"2024020318322710000_bib72","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1359\/jbmr.2002.17.7.1151","article-title":"Commentary on clinical safety of recombinant human parathyroid hormone. 1\u201334 in the treatment of osteoporosis in men and postmenopausal women","volume":"17","author":"Tashjian","year":"2002","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib73","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1359\/JBMR.050507","article-title":"Primary hyperparathyroidism and osteosarcoma; examination of a large cohort identifies three cases of fibroblastic osteosarcoma","volume":"20","author":"Jimenez","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib74","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1210\/endo-16-5-547","article-title":"On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol","volume":"16","author":"Selye","year":"1932","journal-title":"Endocrinology."},{"issue":"5","key":"2024020318322710000_bib75","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev."},{"issue":"2","key":"2024020318322710000_bib76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9343(97)00270-2","article-title":"Survival after the diagnosis of hyperparathyroidism: a population-based study","volume":"104","author":"Wermers","year":"1998","journal-title":"Am J Med."},{"issue":"6","key":"2024020318322710000_bib77","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics of teriparatide (rhPTH[1\u201334]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcif Tissue Int."},{"issue":"3","key":"2024020318322710000_bib78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0009-9236(97)90169-7","article-title":"Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1\u201384)] in healthy postmenopausal volunteers","volume":"61","author":"Schwietert","year":"1997","journal-title":"Clin Pharmacol Ther."},{"issue":"13","key":"2024020318322710000_bib79","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"issue":"4","key":"2024020318322710000_bib80","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2024020318322710000_bib81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int."},{"issue":"9","key":"2024020318322710000_bib82","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1210\/jc.2006-2439","article-title":"Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide","volume":"92","author":"Miller","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024020318322710000_bib83","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1185\/030079906X100159","article-title":"Initial experience with teriparatide in the United States","volume":"22","author":"Gold","year":"2006","journal-title":"Curr Med Res Opin."},{"issue":"13","key":"2024020318322710000_bib84","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"2024020318322710000_bib85","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1359\/jbmr.081233","article-title":"PTH (1\u201334) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation","volume":"24","author":"Theman","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020318322710000_bib86","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.clinthera.2007.09.024","article-title":"Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study","volume":"29","author":"Adachi","year":"2007","journal-title":"Clin Ther."},{"key":"2024020318322710000_bib87","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00198-008-0766-0","article-title":"Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis","volume":"20","author":"Lindsay","year":"2009","journal-title":"Osteoporos Int."},{"key":"2024020318322710000_bib88","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","article-title":"Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)","volume":"85","author":"Langdahl","year":"2009","journal-title":"Calcif Tissue Int."},{"key":"2024020318322710000_bib89","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00223-008-9152-3","article-title":"PTH (1\u201384) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy","volume":"83","author":"Fogelman","year":"2008","journal-title":"Calcif Tissue Int."},{"key":"2024020318322710000_bib90","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","article-title":"Persistence with teriparatide in patients with osteoporosis: the UK experience","volume":"17","author":"Arden","year":"2006","journal-title":"Osteoporos Int."},{"key":"2024020318322710000_bib91","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-008-0698-8","article-title":"Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience","volume":"20","author":"Briot","year":"2009","journal-title":"Osteoporos Int."},{"key":"2024020318322710000_bib92","first-page":"28","article-title":"Improved adherence with PTH (1\u201384) for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis","author":"Black","year":"2012","journal-title":"Osteoporosis Int. Epub."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1800","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/12\/2419\/56560823\/1800_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/12\/2419\/56560823\/1800_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:48:06Z","timestamp":1710341286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/27\/12\/2419-2428\/7598335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,19]]},"references-count":92,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,11,19]]},"published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1800","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,12,1]]},"published":{"date-parts":[[2012,11,19]]}}}